These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25011656)

  • 1. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.
    Zoller M; Maier B; Hornuss C; Neugebauer C; Döbbeler G; Nagel D; Holdt LM; Bruegel M; Weig T; Grabein B; Frey L; Teupser D; Vogeser M; Zander J
    Crit Care; 2014 Jul; 18(4):R148. PubMed ID: 25011656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Manini P; Andreoli R; Cabassi A
    Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring: linezolid too?
    Richards GA; Brink AJ
    Crit Care; 2014 Sep; 18(5):525. PubMed ID: 25673559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid clearance during continuous venovenous hemodiafiltration: a case report.
    Kraft MD; Pasko DA; DePestel DD; Ellis JJ; Peloquin CA; Mueller BA
    Pharmacotherapy; 2003 Aug; 23(8):1071-5. PubMed ID: 12921253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
    Luque S; Grau S; Alvarez-Lerma F; Ferrández O; Campillo N; Horcajada JP; Basas M; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.
    Myrianthefs P; Markantonis SL; Vlachos K; Anagnostaki M; Boutzouka E; Panidis D; Baltopoulos G
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3971-6. PubMed ID: 16982782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Rimmelé T; Djabarouti S; Toutain J; Chassard D; Saux MC; Allaouchiche B
    Crit Care Med; 2005 Jul; 33(7):1529-33. PubMed ID: 16003058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Sagripanti S; Manini P; Andreoli R; Cabassi A
    Crit Care Med; 2004 Dec; 32(12):2437-42. PubMed ID: 15599148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases.
    Pea F; Viale P; Lugano M; Pavan F; Scudeller L; Della Rocca G; Furlanut M
    Am J Kidney Dis; 2004 Dec; 44(6):1097-102. PubMed ID: 15558532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.
    Buerger C; Plock N; Dehghanyar P; Joukhadar C; Kloft C
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2455-63. PubMed ID: 16801426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Caillault-Sergent A; Djabarouti S; Guillaume C; Xuereb F; Bouvet L; Rimmelé T; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2012 May; 67(5):1207-10. PubMed ID: 22351682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study.
    Cai Y; Chai D; Falagas ME; Karageorgopoulos DE; Wang R; Bai N; Liang B
    Expert Opin Investig Drugs; 2013 Mar; 22(3):309-15. PubMed ID: 23360474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients.
    Yagi T; Naito T; Doi M; Nagura O; Yamada T; Maekawa M; Sato S; Kawakami J
    Int J Antimicrob Agents; 2013 Oct; 42(4):329-34. PubMed ID: 23988716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
    Zander J; Döbbeler G; Nagel D; Maier B; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Crit Care; 2016 Apr; 20():79. PubMed ID: 27039986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection.
    Eslam RB; Burian A; Vila G; Sauermann R; Hammer A; Frenzel D; Minichmayr IK; Kloft C; Matzneller P; Oesterreicher Z; Zeitlinger M
    J Clin Pharmacol; 2014 Sep; 54(9):1058-62. PubMed ID: 24677034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.